CAS 901119-35-5
:Fostamatinib
Description:
Fostamatinib is an oral medication primarily used as a treatment for certain autoimmune conditions, particularly chronic immune thrombocytopenia (ITP). It functions as a spleen tyrosine kinase (SYK) inhibitor, which plays a crucial role in the signaling pathways of immune cells. By inhibiting SYK, Fostamatinib helps modulate the immune response, reducing platelet destruction in ITP patients. The substance is characterized by its molecular formula, which reflects its complex structure, and it typically appears as a white to off-white powder. Fostamatinib is administered in tablet form and is metabolized in the liver, with its pharmacokinetics influenced by various factors, including food intake. Common side effects may include diarrhea, hypertension, and liver enzyme elevations, necessitating monitoring during treatment. As with any medication, it is essential for patients to discuss potential risks and benefits with their healthcare provider before starting therapy. Overall, Fostamatinib represents a targeted approach in managing autoimmune disorders, showcasing the advancements in pharmacological treatments.
Formula:C23H26FN6O9P
InChI:InChI=1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29)
InChI key:InChIKey=GKDRMWXFWHEQQT-UHFFFAOYSA-N
SMILES:C(OP(=O)(O)O)N1C=2C(OC(C)(C)C1=O)=CC=C(NC3=NC(NC4=CC(OC)=C(OC)C(OC)=C4)=NC=C3F)N2
Synonyms:- R 788
- 6-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-4-[(phosphonooxy)methyl]-2H-pyrido[3,2-b]-1,4-oxazin-3(4H)-one
- 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-4-[(phosphonooxy)methyl]-
- Fostamatinib
- RT788
- R7935788
- FOSTAMATINIB (R788);R788
- R788 free base
- R788, >=99%
- R788 5MG
- (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2,3-dihydropyrido[3,2-b][1,4]oxazin-4-yl)methyl dihydrogen phosphate
- R788
- NSC-745942
- FostaMatinib (R788)
- Fostamatinib USP/EP/BP
- CS-883
- [6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl dihydrogen phosphate
- R-935788
- R788 (Fostamatinib, FosD, tamatinib fosdium)
- FostaMatinib DisodiuM
- See more synonyms
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
Found 11 products.
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
(6-((5-Fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl dihydrogen phosphate
CAS:(6-((5-Fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl dihydrogen phosphateFormula:C23H26FN6O9PPurity:98%Molecular weight:580.46Fostamatinib
CAS:Fostamatinib (R788)(IC50 of 41 nM), which is a prodrug of the active metabolite R406, is a Syk inhibitor. It does not work on Lyn.Formula:C23H26FN6O9PPurity:93.08% - 99.58%Color and Shape:SolidMolecular weight:580.46R 788 Sodium Salt Hydrate
CAS:Controlled ProductApplications R 788 Sodium Salt Hydrate is a sodium hydrate form of R 788 which is a selective spleen tyrosine kinase (Syk) inhibitor. It may be used in the treatment of autoimmune diseases such as type 1 diabetes and has been tested in the treatment of rheumatoid athritis, leukemia and lymphoma.
References Colonnna, L., et al.: J. Immunol., 185, 1532 (2010); McAdoo, S., et al.: Drug Future, 36, 273 (2011); Efremov, D., et al.: Expert Opin. Inv. Drug., 20, 623 (2011);Formula:C23H24FN6Na2O9P•x(H2O)Color and Shape:NeatMolecular weight:624.421801Fostamatinib
CAS:Inhibitor of spleen tyrosine kinase SYK; prodrug of R406Formula:C23H26FN6O9PPurity:Min. 95%Molecular weight:580.46 g/mol
